Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

639 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study.
Zolotov E, Kabat M, Parmar H, Anand P, Zenreich J, Aleman A, Phull P, Doucette K, Vesole DH, Siegel DS, Biran N. Zolotov E, et al. Among authors: aleman a. Leuk Lymphoma. 2024 Dec;65(13):2000-2008. doi: 10.1080/10428194.2024.2385501. Epub 2024 Jul 31. Leuk Lymphoma. 2024. PMID: 39082756
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Vesole DH, Bilotti E, Richter JR, McNeill A, McBride L, Raucci L, Anand P, Bednarz U, Ivanovski K, Smith J, Batra V, Aleman A, Sims T, Guerrero L, Mato A, Siegel DS. Vesole DH, et al. Among authors: aleman a. Br J Haematol. 2015 Oct;171(1):52-9. doi: 10.1111/bjh.13517. Epub 2015 May 27. Br J Haematol. 2015. PMID: 26018491 Free article. Clinical Trial.
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.
Varma G, Fogel L, Gordon B, Saldarriaga MM, Ahn J, Aleman A, Caro J, Rosenberg MC, Monge J, Parmar H, Kaminetzky D, Moskovits T, Siegel DS, Morgan GJ, Niesvizky R, Davies FE, Biran N. Varma G, et al. Among authors: aleman a. Leuk Lymphoma. 2025 Jan 5:1-10. doi: 10.1080/10428194.2024.2446617. Online ahead of print. Leuk Lymphoma. 2025. PMID: 39756041
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.
Jatiani SS, Aleman A, Madduri D, Chari A, Cho HJ, Richard S, Richter J, Brody J, Jagannath S, Parekh S. Jatiani SS, et al. Among authors: aleman a. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):632-636.e1. doi: 10.1016/j.clml.2020.04.020. Epub 2020 May 11. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32553791 Free PMC article. No abstract available.
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, Ghodke-Puranik Y, Shah GL, Lesokhin A, Giralt S, Thibaud S, Rossi A, Rodriguez C, Sanchez L, Richter J, Richard S, Cho HJ, Chari A, Usmani SZ, Jagannath S, Shah UA, Mailankody S, Parekh S. Van Oekelen O, et al. Among authors: aleman a. Blood. 2023 Feb 16;141(7):756-765. doi: 10.1182/blood.2022017848. Blood. 2023. PMID: 36327160 Free PMC article.
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
Restrepo P, Bhalla S, Ghodke-Puranik Y, Aleman A, Leshchenko V, Melnekoff DT, Agte S, Jiang J, Madduri D, Richter J, Richard S, Chari A, Cho HJ, Jagannath S, Walker CJ, Landesman Y, Laganà A, Parekh S. Restrepo P, et al. Among authors: aleman a. JCO Precis Oncol. 2022 Jun;6:e2200147. doi: 10.1200/PO.22.00147. JCO Precis Oncol. 2022. PMID: 35704796 Free PMC article.
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.
Aleman A, Upadhyaya B, Tuballes K, Kappes K, Gleason CR, Beach K, Agte S, Srivastava K; PVI/Seronet Study Group; Van Oekelen O, Barcessat V, Bhardwaj N, Kim-Schulze S, Gnjatic S, Brown B, Cordon-Cardo C, Krammer F, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Aleman A, et al. Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19. Cancer Cell. 2021. PMID: 34706273 Free PMC article. No abstract available.
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. Mouhieddine TH, et al. Among authors: aleman a. Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923. Blood Adv. 2023. PMID: 36018226 Free PMC article. Clinical Trial.
639 results